Skip to Content

Drug interactions between sarecycline and tipranavir

Results for the following 2 drugs:
sarecycline
tipranavir

Interactions between your drugs

Moderate

tipranavir sarecycline

Applies to: tipranavir and sarecycline

Consumer information for this interaction is not currently available.

MONITOR: Coadministration with sarecycline may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine, kidney, and/or liver due to inhibition of P-gp-mediated efflux by sarecycline. When the probe P-gp substrate digoxin was coadministered with a single 150 mg dose of sarecycline, digoxin peak plasma concentration (Cmax) increased by 26%.

MANAGEMENT: Caution is advised when sarecycline is used concurrently with drugs that are P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever sarecycline is added to or withdrawn from therapy.

References

  1. "Product Information. Seysara (sarecycline)." Allergan Inc, Irvine, CA.

Drug and food interactions

Moderate

tipranavir food

Applies to: tipranavir

Tipranavir should be taken with food. This helps to reduce the gastrointestinal side effects of ritonavir, which you must also take with tipranavir in order to achieve effective blood levels of the medication against HIV. Talk to your doctor or pharmacist if you have any questions on how to use these medications properly.

Switch to professional interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide